Right Test, Right Setting: Balancing Cost, Feasibility & Fit-for-Purpose in Liquid Biopsies
- How clinical use case, risk tolerance, and decision impact should dictate assay design, validation depth, and deployment setting across screening, MRD, and treatment monitoring
- Practical trade-offs between analytical performance, cost, turnaround time, infrastructure, and scalability when moving liquid biopsy tools from trials into routine practice
- Where AI can meaningfully enhance liquid biopsy workflows, and where added model complexity creates validation, regulatory, or adoption challenges without clear clinical gain